Publication:
A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment.

dc.contributor.authorPérez-Antón, Elena
dc.contributor.authorEgui, Adriana
dc.contributor.authorThomas, M Carmen
dc.contributor.authorCarrilero, Bartolomé
dc.contributor.authorSimón, Marina
dc.contributor.authorLópez-Ruz, Miguel Ángel
dc.contributor.authorSegovia, Manuel
dc.contributor.authorLópez, Manuel Carlos
dc.date.accessioned2023-02-09T10:41:08Z
dc.date.available2023-02-09T10:41:08Z
dc.date.issued2021-02-04
dc.description.abstractSigns of senescence and the late stages of differentiation associated with the more severe forms of Chagas disease have been described in the Trypanosoma cruzi antigen-specific CD4+ T-cell population. However, the mechanisms involved in these functions are not fully known. To date, little is known about the possible impact of benznidazole treatment on the T. cruzi-specific functional response of CD4+ T cells. The functional capacity of CD4+ T cells was analyzed by cytometric assays in chronic Chagas disease patients, with indeterminate form (IND) and cardiac alterations (CCC) (25 and 15, respectively) before and after benznidazole treatment. An increase in the multifunctional capacity (expression of IFN-γ, IL-2, TNF-α, perforin and/or granzyme B) of the antigen-specific CD4+ T cells was observed in indeterminate versus cardiac patients, which was associated with the reduced coexpression of inhibitory receptors (2B4, CD160, CTLA-4, PD-1 and/or TIM-3). The functional profile of these cells shows statistically significant differences between IND and CCC (p A CD4+ T cell dysfunctional process was detected in chronic Chagas disease patients, being more exacerbated in those patients with cardiac symptoms. After short-term benznidazole treatment (9-12 months), indeterminate patients showed a significant increase in the frequency of multifunctional antigen-specific CD4+ T cells.
dc.identifier.doi10.1371/journal.pntd.0009059
dc.identifier.essn1935-2735
dc.identifier.pmcPMC7888659
dc.identifier.pmid33539379
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888659/pdf
dc.identifier.unpaywallURLhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0009059&type=printable
dc.identifier.urihttp://hdl.handle.net/10668/17104
dc.issue.number2
dc.journal.titlePLoS neglected tropical diseases
dc.journal.titleabbreviationPLoS Negl Trop Dis
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.numbere0009059
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdult
dc.subject.meshAntibodies, Protozoan
dc.subject.meshAntiprotozoal Agents
dc.subject.meshCD4-Positive T-Lymphocytes
dc.subject.meshChagas Disease
dc.subject.meshFemale
dc.subject.meshGranzymes
dc.subject.meshHumans
dc.subject.meshInterferon-gamma
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNitroimidazoles
dc.subject.meshPerforin
dc.subject.meshSpain
dc.subject.meshTrypanosoma cruzi
dc.subject.meshYoung Adult
dc.titleA proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number15
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7888659.pdf
Size:
2.62 MB
Format:
Adobe Portable Document Format